Selection process for botulinum toxin injections in patients with chronic-stage hemiplegic stroke: a qualitative study.
Adult
Aged
Botulinum Toxins, Type A
/ administration & dosage
Chronic Disease
Decision Making
Female
Hemiplegia
/ drug therapy
Humans
Injections, Intramuscular
Male
Mental Status and Dementia Tests
Middle Aged
Muscle Spasticity
/ drug therapy
Patient Selection
Qualitative Research
Stroke
/ complications
Botulinum toxin
Decision-making
Grounded theory
Hemiplegia
Qualitative research
Spasticity
Stroke
Journal
BMC medical informatics and decision making
ISSN: 1472-6947
Titre abrégé: BMC Med Inform Decis Mak
Pays: England
ID NLM: 101088682
Informations de publication
Date de publication:
19 12 2019
19 12 2019
Historique:
received:
12
07
2018
accepted:
11
12
2019
entrez:
21
12
2019
pubmed:
21
12
2019
medline:
29
4
2020
Statut:
epublish
Résumé
Botulinum toxin (BT) injection is a new treatment for spasticity with hemiplegia after stroke. How a patient decides to receive BT injections after becoming aware of the treatment remains unclear. In this exploratory qualitative study, we aimed to investigate patients' decision-making about treatment strategies in collaboration with family and health professionals and to identify conflicts in patients' feelings about BT treatment. The study included six patients with stroke sequelae. Data were collected using comprehensive interviews and were analyzed using the grounded theory approach and trajectory equifinality modeling. After patients learned about BT treatment, they clearly exhibited the following two concurrent perceptions: "the restriction of one's life due to disabilities" and "the ability to do certain things despite one's disabilities." Some patients reported a "fear of not being able to maintain the status quo owing to the side effects of BT." To alleviate this fear, timely support from family members was offered, and patients overcame anxiety through creative thinking. However, there were also expressions that revealed patients' difficulties dealing with negative events. These factors influenced the patients' development of "expectations of BT" or "hesitations about BT." To establish treatment strategies in collaboration with patients, healthcare professionals should show supportive attitudes and have discussions with patients and their family members to help patients resolve their conflicts and should establish treatment strategies that maintain the positive aspects of patients' lives.
Sections du résumé
BACKGROUND
Botulinum toxin (BT) injection is a new treatment for spasticity with hemiplegia after stroke. How a patient decides to receive BT injections after becoming aware of the treatment remains unclear. In this exploratory qualitative study, we aimed to investigate patients' decision-making about treatment strategies in collaboration with family and health professionals and to identify conflicts in patients' feelings about BT treatment.
METHODS
The study included six patients with stroke sequelae. Data were collected using comprehensive interviews and were analyzed using the grounded theory approach and trajectory equifinality modeling.
RESULTS
After patients learned about BT treatment, they clearly exhibited the following two concurrent perceptions: "the restriction of one's life due to disabilities" and "the ability to do certain things despite one's disabilities." Some patients reported a "fear of not being able to maintain the status quo owing to the side effects of BT." To alleviate this fear, timely support from family members was offered, and patients overcame anxiety through creative thinking. However, there were also expressions that revealed patients' difficulties dealing with negative events. These factors influenced the patients' development of "expectations of BT" or "hesitations about BT."
CONCLUSIONS
To establish treatment strategies in collaboration with patients, healthcare professionals should show supportive attitudes and have discussions with patients and their family members to help patients resolve their conflicts and should establish treatment strategies that maintain the positive aspects of patients' lives.
Identifiants
pubmed: 31856809
doi: 10.1186/s12911-019-1003-9
pii: 10.1186/s12911-019-1003-9
pmc: PMC6923967
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
280Références
Acta Neurol Scand. 2013 Nov;128(5):305-10
pubmed: 23594079
Med Decis Making. 2000 Jan-Mar;20(1):112-27
pubmed: 10638544
J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):217-21
pubmed: 10896696
Acta Neurol Scand Suppl. 2010;(190):62-6
pubmed: 20586738
Phys Ther. 1987 Feb;67(2):206-7
pubmed: 3809245
J Am Geriatr Soc. 2003 Nov;51(11):1610-4
pubmed: 14687391
J Voice. 2007 Mar;21(2):231-47
pubmed: 16564675
Mov Disord. 2009 Apr 30;24(6):801-12
pubmed: 19224614
Phys Ther. 1966 Apr;46(4):357-75
pubmed: 5907254
Health Expect. 2003 Jun;6(2):97-109
pubmed: 12752738
Syst Rev. 2015 Jun 13;4:86
pubmed: 26071172
Med J Aust. 2014 Jul 7;201(1):35-9
pubmed: 24999896
Arch Phys Med Rehabil. 2008 May;89(5):799-806
pubmed: 18452724
Arch Phys Med Rehabil. 2004 Jul;85(7):1063-9
pubmed: 15241751
J Geriatr Psychiatry Neurol. 2010 Mar;23(1):3-8
pubmed: 19661490
Stroke. 2008 Oct;39(10):2803-8
pubmed: 18635841
Patient Educ Couns. 1998 Mar;33(3):267-79
pubmed: 9731164
Disabil Rehabil. 1994 Jul-Sep;16(3):110-8
pubmed: 7919394
N Engl J Med. 1988 Dec 22;319(25):1635-8
pubmed: 3200278
Aust Occup Ther J. 2015 Feb;62(1):27-40
pubmed: 25649033